關節疼痛注射市場：機會、成長要素、產業趨勢分析及預測（2026-2035年）

全球關節疼痛注射市場預計到 2025 年將達到 61 億美元，到 2035 年將達到 128 億美元，年複合成長率為 7.8%。

市場成長主要受全球肌肉骨骼疾病負擔加重的推動，這些疾病仍然是長期殘疾和生活品質下降的主要原因。隨著關節相關疾病逐漸限制活動能力和日常功能，對無需手術即可緩解疼痛的治療方法的需求持續成長。關節疼痛注射是一種微創療法，旨在減輕發炎、緩解不適並恢復患有退化性疾病和創傷相關疾病患者的關節活動範圍。市場正穩步轉向先進的再生醫學和生物注射解決方案，這些方案專注於組織修復和功能恢復，而非短期症狀管理。正面的臨床結果和患者活動能力的改善增強了人們對這些治療方法的信心。隨著人口老化，關節炎盛行率不斷上升，以及身體活躍人口關節損傷的增加，也推動了市場成長。年輕患者也開始採用注射療法來維持活動量並延緩手術，將市場拓展到傳統老齡化相關族群之外。

2025年，透明質酸市場規模預計將達39億美元。該市場憑藉其在改善關節潤滑、減少摩擦和增強退化性關節疾病患者活動能力方面的顯著作用，保持著強勁的市場地位。其良好的安全性、較高的臨床接受度和廣泛的臨床應用，並持續推動透明質酸產品的廣泛應用。關節退化性疾病診斷率的不斷提高，進一步增強了市場對透明質酸注射療法的持續需求。

預計到2035年，膝關節疾病市場規模將達96億美元。這一成長主要受人口老化、生活方式因素和代謝性疾病等因素導致的膝關節退化性疾病發生率上升所驅動。大量的治療需求和多種注射治療方案的出現，使膝關節成為治療頻率最高的關節，鞏固了其在臨床實踐和門診治療中的主導地位。

預計到2025年，北美關節疼痛注射市場將繼續保持其領先區域市場的地位，佔據47.1%的市場佔有率。這一優勢得益於大規模的關節疾病患者群體、先進的醫療基礎設施以及創新注射療法的廣泛應用。有利的報銷制度、高昂的醫療支出、較高的患者意識以及對非手術治療方法的早期採用，持續推動全部區域的市場成長。主要行業參與者的存在進一步鞏固了該地區的主導地位。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 產業影響因素
  • 促進要素
    • 骨關節炎和肌肉骨骼疾病的發生率不斷上升
    • 微創、非手術治療方法的普及率不斷提高
    • 生物醫學和再生醫學的進展
    • 提高醫療意識和改善醫療服務取得途徑
  • 產業潛在風險與挑戰
    • 有副作用風險且療效不一。
    • 嚴格的監管要求
  • 市場機遇
    • 擴大整形外科生物療法
    • 對個人化和聯合治療的需求日益成長
• 成長潛力分析
• 監管環境
• 科技趨勢
  • 當前技術趨勢
  • 新興技術
• 救贖方案
• 關節疼痛的流行病學概況
• 管道分析
• 定價分析
• 未來市場趨勢
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 公司市佔率分析
  • 世界
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 重大進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章 依注射類型分類的市場估算與預測，2022-2035年

• 玻尿酸注射
• 皮質類固醇注射
• 富血小板血漿注射
• 其他

第6章 依關節類型分類的市場估計與預測，2022-2035年

• 膝關節
• 肩關節和肘關節
• 踝關節及髖關節
• 其他

第7章 依最終用途分類的市場估計與預測，2022-2035年

• 醫院
• 整形外科和疼痛診所
• 門診手術中心
• 其他

第8章 2022-2035年各地區市場估算與預測

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Anika Therapeutics
• Arthrex
• Bioventus
• Cipla
• Emcyte Corporation
• Ferring
• Lifecore Biomedical
• OrthogenRx
• Pacira BioSciences（Flexion）
• Pfizer
• Sanofi
• SEIKAGAKU CORPORATION
• Stryker Corporation
• Zimmer Biomet Holdings

The Global Joint Pain Injections Market was valued at USD 6.1 billion in 2025 and is estimated to grow at a CAGR of 7.8% to reach USD 12.8 billion by 2035.

Market growth is supported by the increasing global burden of musculoskeletal disorders, which remain a major cause of long-term disability and reduced quality of life. As joint-related conditions increasingly limit mobility and daily function, demand continues to rise for treatment options that offer pain relief without surgical intervention. Joint pain injections represent minimally invasive therapies designed to reduce inflammation, relieve discomfort, and restore joint movement in patients affected by degenerative and injury-related conditions. The market is steadily shifting toward advanced regenerative and biologic injection solutions that focus on tissue repair and functional recovery rather than short-term symptom control. Positive clinical outcomes and improved patient mobility have strengthened confidence in these therapies. Growth is further supported by rising arthritis prevalence among aging populations and increasing joint injuries among physically active individuals. Younger patients are also adopting injectable treatments to maintain activity levels and postpone surgical procedures, broadening the market beyond traditional age-related use.

The hyaluronic acid segment reached USD 3.9 billion in 2025. This segment maintains a strong position due to its established role in improving joint lubrication, minimizing friction, and enhancing movement in degenerative joint conditions. Its favorable safety profile, strong clinical acceptance, and broad availability across healthcare settings continue to support widespread adoption. Increasing diagnosis rates of joint degeneration further reinforce the sustained demand for hyaluronic acid-based injection therapies.

The knee segment is projected to reach USD 9.6 billion by 2035. This growth is driven by the rising occurrence of knee joint degeneration associated with aging populations, lifestyle-related factors, and metabolic health conditions. High treatment volumes and the availability of multiple injectable therapy options have positioned the knee as the most frequently treated joint, strengthening its dominance across clinical practices and outpatient care facilities.

North America Joint Pain Injections Market accounted for 47.1% share in 2025, maintaining its position as the leading regional market. This dominance is supported by a large patient base affected by joint disorders, advanced healthcare infrastructure, and widespread use of innovative injection therapies. Favorable reimbursement frameworks, high healthcare spending, strong patient awareness, and early adoption of non-surgical treatment approaches continue to drive market growth across the region. The presence of major industry participants further enhances regional leadership.

Key companies operating in the Joint Pain Injections Market include Zimmer Biomet Holdings, Sanofi, Pfizer, Stryker Corporation, Anika Therapeutics, SEIKAGAKU CORPORATION, Bioventus, Arthrex, OrthogenRx, Lifecore Biomedical, Pacira BioSciences (Flexion), Emcyte Corporation, Cipla, and Ferring. Companies in the joint pain injections market are implementing targeted strategies to strengthen market positioning and sustain growth. Significant investments are being made in research and development to advance biologic and regenerative injection technologies with improved clinical outcomes. Strategic collaborations with healthcare providers and orthopedic specialists are expanding treatment accessibility and clinical adoption. Firms are also focusing on portfolio diversification to address multiple joint types and disease stages. Geographic expansion into emerging markets and strengthening distribution networks remain key priorities.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Injection type trends
  • 2.2.3 Joint type trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of osteoarthritis and musculoskeletal disorders
    • 3.2.1.2 Growing adoption of minimally invasive and non-surgical therapies
    • 3.2.1.3 Advancements in biologic and regenerative therapies
    • 3.2.1.4 Rising awareness and healthcare access
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Risk of adverse reactions and variable efficacy
    • 3.2.2.2 Stringent regulatory requirements
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of orthobiologic therapies
    • 3.2.3.2 Growing demand for personalized and combination therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Reimbursement scenario
• 3.7 Joint pain epidemiology scenario
• 3.8 Pipeline analysis
• 3.9 Pricing analysis
• 3.10 Future market trends
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Injection Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Hyaluronic acid injections
• 5.3 Corticosteroid injections
• 5.4 Platelet rich plasma injections
• 5.5 Other injection types

Chapter 6 Market Estimates and Forecast, By Joint Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Knee
• 6.3 Shoulder and elbow
• 6.4 Ankle and hip
• 6.5 Other joint types

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Orthopedic/pain clinics
• 7.4 Ambulatory surgical centers
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Anika Therapeutics
• 9.2 Arthrex
• 9.3 Bioventus
• 9.4 Cipla
• 9.5 Emcyte Corporation
• 9.6 Ferring
• 9.7 Lifecore Biomedical
• 9.8 OrthogenRx
• 9.9 Pacira BioSciences (Flexion)
• 9.10 Pfizer
• 9.11 Sanofi
• 9.12 SEIKAGAKU CORPORATION
• 9.13 Stryker Corporation
• 9.14 Zimmer Biomet Holdings